#biotech — FinScans

News 📈 Stocks

North Immunology to Go Public via $180M Reverse Merger with Aethlon Medical

September 18, 2026 (7 days ago)

North Immunology secures $180 million and a Nasdaq listing via a reverse merger with Aethlon Medical to advance its dual-pathway inflammatory drug,…

NRTX AEMD KYMR +3

🌍 AMERICAS Read More →

News 📈 Stocks

Biotech IPO Market Faces Scrutiny as 8 Firms Seek Capital for Clinical Trials

September 18, 2026 (7 days ago)

Investors are prioritizing clinical-stage biotechs with proven potential, as eight companies navigate the IPO process with varying degrees of market readiness and…

Grifols Electra Therapeutics Tarsier Therapeutics +6

🌍 GLOBAL Read More →

News 📈 Stocks

Amgen Shares Offer Defensive Hedge Amid Market Volatility and Economic Risks

September 18, 2026 (8 days ago)

Amgen remains a defensive staple for investors, leveraging a strong dividend yield and diversified drug pipeline to navigate broader economic instability and…

AMGN NVS NVDA

🌍 AMERICAS Read More →

News 📈 Stocks

Merck Shares Rally 11% on Positive Phase 3 mRNA Cancer Therapy Results

September 17, 2026 (8 days ago)

Merck stock surges 11% following breakthrough Phase 3 cancer trial results with Moderna, while the company maintains a strong dividend profile and…

MRK MRNA GOOGL +1

🌍 AMERICAS Read More →

News 📈 Stocks

BioCryst Targets Rare Disease Expansion After Reaching Profitability

September 17, 2026 (8 days ago)

BioCryst aims to diversify its rare disease portfolio using Orladeyo's cash flow, though significant debt obligations and clinical execution risks remain key…

BCRX TAK

🌍 AMERICAS Read More →

Analyst 📈 Stocks

Tempus AI Rallies 30% as Morgan Stanley Upgrades Revenue Outlook

September 17, 2026 (8 days ago)

Tempus AI stock jumped 30% after Morgan Stanley highlighted $330M-$400M in potential annual revenue gains from new diagnostic reimbursement pricing, fueling investor…

TEM

🌍 AMERICAS Read More →

Insider 📈 Stocks

Inhibrx CEO Mark Lappe Purchases $2.6M in Shares Following Trial Success

September 17, 2026 (8 days ago)

CEO Mark Lappe's $2.6 million share purchase underscores internal optimism at Inhibrx Biosciences as the clinical-stage firm advances its proprietary protein engineering…

INBX

🌍 AMERICAS Read More →

News 🌐 Macro — 📊 Neutral

BlossomHill Therapeutics Shares Rally 4.4% on Positive Lung Cancer Trial Data

September 17, 2026 (9 days ago)

BlossomHill Therapeutics stock gains 4.4% as the company reports a 45% objective response rate for its BH-30643 lung cancer treatment in the…

MindWalk Reports 21% Revenue Growth as ReefIQ AI Platform Scales

September 16, 2026 (9 days ago)

MindWalk pivots to partnership-based AI discovery, reporting 21% revenue growth and securing $30 million in financing to scale its ReefIQ platform across…

Geron Raises 2026 RYTELO Revenue Outlook to $230M-$240M on Strong Adoption

September 16, 2026 (9 days ago)

Geron reports record quarterly revenue of $57.5 million and raises its 2026 RYTELO revenue guidance to $230M-$240M as the company accelerates its…

GERN

🌍 AMERICAS Read More →

IPO 📈 Stocks

Electra Therapeutics Targets $342M IPO to Advance Lead Drug Ipsoprubart

September 15, 2026 (10 days ago)

Electra Therapeutics seeks a $342 million Nasdaq listing to fuel Phase III trials for its lead hyperinflammatory syndrome treatment, ipsoprubart, following strong…

ETRA

🌍 AMERICAS Read More →

Earnings 📈 Stocks

MindWalk Reports 21% Revenue Growth and Secures $30M Credit Facility

September 15, 2026 (10 days ago)

MindWalk Holdings posts 21% revenue growth and expands gross margins to 59%, bolstered by a new $30 million credit facility to accelerate…

HYFT

🌍 AMERICAS Read More →